Hernexeos in Jordan
How patients in Jordan access Hernexeos (daridorexant class) via Named Patient Program.
Hernexeos - overview
Hernexeos (daridorexant class) is manufactured by Idorsia (verify) and indicated for Insomnia — OUT OF SCOPE (daridorexant class = DEA Schedule IV dual orexin receptor antagonist; PlatformCo does not handle controlled substances. Fatima's DEA-registered entity may pursue separately. Note: drug-name mapping 'Hernexeos' is uncertain — verify FDA label before any future action.). It is a HER2 TKI approved by the US FDA in 2025 and may be accessible to patients in Jordan through a Named Patient Program or personal-import pathway.
Access in Jordan
Jordan's JFDA operates a compassionate-use framework for unregistered drugs; requires physician and JFDA approval.
How Reserve Meds coordinates access in Jordan
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Jordan-specific eligibility.
- Treating physician in Jordan issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Hernexeos from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Jordan.
Typical timeline for Jordan
End-to-end, most requests are completed in 2-6 weeks. Jordan's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Jordan ask
- Is the pathway legal in Jordan? Yes - it operates under Jordan's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Jordan able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.